OncoSil Medical Ltd shines under broker spotlight
OncoSil has been receiving some strong broker attention recently, as the company moves closer to commercial revenue.
Company
OncoSil Medical Ltd
ASX:OSL
OncoSil Medical is a global medical device company focused on Interventional Oncology. The company's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.
61 stories · page 2 of 4
Oncosil Medical Ltd: Commercial Revenues Closer
Bell Potter noted: "The awarding of the IDE is a major step forward for this first in class therapy, consequently the valuation is raised by 10% to $0.33."
OncoSil Medical Ltd: IDE Approval from the U.S. Food and Drug Administration
Daniel Kenny, CEO, commented: “We are delighted to receive FDA approval for the IDE which is a significant milestone in our regulatory pathway and a validation of our product and supporting processes to commence this important clinica
OncoSil Medical Ltd confident of a successful outcome with the FDA
OncoSil has continued to make progress with its two key regulatory filings during the June quarter 2016, which remain the primary focus and value enablers for the OncoSil™ technology.
OncoSil Medical Ltd remains confident on CE Mark and IDE submissions
Daniel Kenny, CEO, commented: "We are delighted with the progress we have been making to prosecute and progress both our CE mark and IDE submissions."
OncoSil Medical Ltd: Thoughts on OncoSil's regulatory situation
WilsonHTM noted: "If the FDA allows Oncosil’s IDE study in the coming months, then that should correspond to more regular positive new flow over the balance of 2016."
OncoSil Medical Ltd confident CE Mark will be granted in near-term
Daniel Kenny, CEO, said: "Our key focus in the shorter term is to achieve the CE Mark and enable commercial launch and first sales. We remain optimistic about a favourable decision shortly on the CE Mark."
OncoSil Medical Ltd: Van Leeuwenhoek applies $0.80 per share valuation
Van Leeuwenhoek wrote: "Based on our NPV valuation, we believe that OncoSil Medical is substantially undervalued at the current share price of AUD 0.16."
OncoSil Medical updates on CE Mark, Regal Funds joins share register
OncoSil added that it remains confident in its submission for CE Mark being granted, thereby enabling commercial sales to commence in the European Union and application for TGA approval in Australia.
OncoSil Medical: Speculative Buy and $0.50 target from broker
WilsonHTM said: "We maintain a Speculative Buy. No change to target price of 50 cps which was pre-emptively diluted for anticipated capital raising event(s) in FY16-17."
OncoSil Medical bags $10M to commercialise cancer treatment
OncoSil Medical has raised A$10 million for the commercialisation of its namesake cancer treatment as a number of regulatory approvals come into focus.
OncoSil Medical share price target upgraded by broker
WilsonHTM has compiled a research report on OncoSil Medical, maintaining a speculative buy rating and upgrading its target price.
ASX closes higher with a strong show by this medical supplier
The Australian All Ordinaries gathered pace today as this value-adding medical supply company helped health care stocks contribute to a widespread turnaround on the local market.
ASX edges down as this medical play marks gains
The Australian All Ordinaries ticked another 0.4% lower today, but a lacklustre session for healthcare stocks didn’t hold back this lifesciences company.
OncoSil Medical files Investigational Device Exemption submission with FDA
Daniel Kenny, CEO, OncoSil, commented: “I am delighted to report that we have filed our Investigational Device Exemption submission with the US FDA. This represents a key milestone in the development timeline for OncoSil™ in the